Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines

Szu Chun Hung, Ko Lin Kuo, Der Cherng Tarng, Chih Cheng Hsu, Mai Szu Wu, Tung Po Huang

研究成果: 雜誌貢獻文章同行評審

15 引文 斯高帕斯(Scopus)

摘要

The introduction of erythropoiesis-stimulating agents (ESAs) markedly improved the lives of many anaemic patients with chronic kidney disease (CKD). In Taiwan, the strategy of management of anaemia in patients with CKD was different from many other parts of the world. In 1996, the National Health Insurance Administration of Taiwan applied a more restrictive reimbursement criteria for ESA use in patients with CKD. ESA is to be initiated when non-dialysis CKD patients have a serum creatinine >6 mg/dL and a hematocrit

原文英語
頁(從 - 到)735-739
頁數5
期刊Nephrology
19
發行號12
DOIs
出版狀態已發佈 - 十二月 1 2014
對外發佈

ASJC Scopus subject areas

  • 腎臟病學
  • 醫藥 (全部)

指紋

深入研究「Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines」主題。共同形成了獨特的指紋。

引用此